Pharmaceuticals

About Eli Lilly’s Recent Announcement of Zepbound DTC Offering

bexib
By bexib 0 Min Read

In this portion of the Pharmaceutical Executive video interview, UpScriptHealth founder and CEO Peter Axe and COO George Jones comment on how Eli Lilly’s recent announcement about selling Zepbound DTC impacts the issue of counterfeit weight loss pills.

You Might Also Like

A “mark” to stardom?: Turkap

Researchers uncover how protein interactions increase risk of Alzheimer’s disease

Potential treatments for all COVID variants

Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Raw Materials Production

FDA expands indication of BioMarin’s Brineura to children with neuronal ceroid lipofuscinosis type 2

Share This Article
Previous Article The Myth That the US is Rapidly Approaching Bankruptcy
Next Article Florida and Texas home price growth slows as inventory soars
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Indian cash -free payments secure the $ 53 million US funded by PUBG Publisher Krafton.
Fintech
Late onboarding promotes clients’ losses at Singapore banks.
Fintech
The gorgeous spa Hotelgal Goma Resort will join the elegant hotel collection as the first member of the North Ireland
Hospitality & Tourism
Peter Navalo says, necessary for Trump’s economic success vision
Manufacturing